A Multiepitope Peptide, rOmp22, Encapsulated in Chitosan-PLGA Nanoparticles as a Candidate Vaccine Against Acinetobacter baumannii Infection

References

• Vazquez-Lopez R, Solano-Galvez SG, Juarez Vignon-Whaley JJ, et al. Acinetobacter baumannii resistance: a real challenge for clinicians. Antibiotics. 2020;9(4):205. doi:10.3390/antibiotics9040205
   Google Scholar
• Chuang YC, Cheng A, Sun HY, et al. Microbiological and clinical characteristics of Acinetobacter baumannii bacteremia: implications of sequence type for prognosis. J Infect. 2019;78(2):106–112. doi:10.1016/j.jinf.2018.10.001
   PubMed Web of Science ®Google Scholar
• Asif M, Alvi IA, Rehman SU. Insight into Acinetobacter baumannii: pathogenesis, global resistance, mechanisms of resistance, treatment options, and alternative modalities. Infect Drug Resist. 2018;11:1249–1260. doi:10.2147/IDR.S166750
   PubMed Web of Science ®Google Scholar
• De Oliveira DMP, Forde BM, Kidd TJ, et al. Antimicrobial Resistance in ESKAPE Pathogens. Clin Microbiol Rev. 2020;33(3):1–49.
   Google Scholar
• Harding CM, Hennon SW, Feldman MF. Uncovering the mechanisms of Acinetobacter baumannii virulence. Nat Rev Microbiol. 2018;16(2):91–102. doi:10.1038/nrmicro.2017.148
   PubMed Web of Science ®Google Scholar
• Mulani MS, Kamble EE, Kumkar SN, Tawre MS, Pardesi KR. Emerging Strategies to Combat ESKAPE pathogens in the era of antimicrobial resistance: a review. Front Microbiol. 2019;10:539.
   PubMed Web of Science ®Google Scholar
• Garcia-Quintanilla M, Pulido MR, Lopez-Rojas R, Pachon J, McConnell MJ. Emerging therapies for multidrug resistant Acinetobacter baumannii. Trends Microbiol. 2013;21(3):157–163.
   PubMed Web of Science ®Google Scholar
• McConnell MJ, Rumbo C, Bou G, Pachon J. Outer membrane vesicles as an acellular vaccine against Acinetobacter baumannii. Vaccine. 2011;29(34):5705–5710.
   PubMed Web of Science ®Google Scholar
• McConnell MJ, Pachon J. Active and passive immunization against Acinetobacter baumannii using an inactivated whole cell vaccine. Vaccine. 2010;29(1):1–5.
   PubMed Web of Science ®Google Scholar
• McConnell MJ, Dominguez-Herrera J, Smani Y, et al. Vaccination with outer membrane complexes elicits rapid protective immunity to multidrug-resistant Acinetobacter baumannii. Infect Immun. 2011;79(1):518–526. doi:10.1128/IAI.00741-10
   PubMed Web of Science ®Google Scholar
• Fattahian Y, Rasooli I, Mousavi Gargari SL, et al. Protection against Acinetobacter baumannii infection via its functional deprivation of biofilm associated protein (Bap). Microb Pathog. 2011;51(6):402–406. doi:10.1016/j.micpath.2011.09.004
   PubMed Web of Science ®Google Scholar
• Bentancor LV, Routray A, Bozkurt-Guzel C, et al. Evaluation of the trimeric autotransporter Ata as a vaccine candidate against Acinetobacter baumannii infections. Infect Immun. 2012;80(10):3381–3388. doi:10.1128/IAI.06096-11
   PubMed Web of Science ®Google Scholar
• Zhang X, Yang T, Cao J, et al. Mucosal immunization with purified OmpA elicited protective immunity against infections caused by multidrug-resistant Acinetobacter baumannii. Microb Pathog. 2016;96:20–25. doi:10.1016/j.micpath.2016.04.019
   PubMed Web of Science ®Google Scholar
• Singh R, Capalash N, Sharma P. Immunoprotective potential of BamA, the outer membrane protein assembly factor, against MDR Acinetobacter baumannii. Sci Rep. 2017;7(1):12411. doi:10.1038/s41598-017-12789-3
   PubMed Web of Science ®Google Scholar
• Bentancor LV, O’Malley JM, Bozkurt-Guzel C, Pier GB, Maira-Litran T. Poly-N-acetyl-beta-(1-6)-glucosamine is a target for protective immunity against Acinetobacter baumannii infections. Infect Immun. 2012;80(2):651–656. doi:10.1128/IAI.05653-11
   PubMed Web of Science ®Google Scholar
• Huang W, Yao Y, Wang S, et al. Immunization with a 22-kDa outer membrane protein elicits protective immunity to multidrug-resistant Acinetobacter baumannii. Sci Rep. 2016;6:20724. doi:10.1038/srep20724
   PubMed Web of Science ®Google Scholar
• Chen W. Current advances and challenges in the development of Acinetobacter vaccines. Hum Vaccin Immunother. 2015;11(10):2495–2500. doi:10.1080/21645515.2015.1052354
   PubMed Web of Science ®Google Scholar
• Li W, Joshi MD, Singhania S, Ramsey KH, Murthy AK. Peptide Vaccine: progress and Challenges. Vaccines. 2014;2(3):515–536. doi:10.3390/vaccines2030515
   PubMedGoogle Scholar
• Baseer S, Ahmad S, Ranaghan KE, Azam SS. Towards a peptide-based vaccine against Shigella sonnei: a subtractive reverse vaccinology based approach. Biologicals. 2017;50:87–99. doi:10.1016/j.biologicals.2017.08.004
   PubMed Web of Science ®Google Scholar
• Abdulla F, Adhikari UK, Uddin MK, Exploring T. B-cell epitopes and designing multi-epitope subunit vaccine targeting integration step of HIV-1 lifecycle using immunoinformatics approach. Microb Pathog. 2019;137:103791. doi:10.1016/j.micpath.2019.103791
   PubMed Web of Science ®Google Scholar
• Babu L, Uppalapati SR, Sripathy MH, Reddy PN. Evaluation of recombinant multi-epitope outer membrane protein-based Klebsiella pneumoniae subunit vaccine in mouse model. Front Microbiol. 2017;8:1805. doi:10.3389/fmicb.2017.01805
   PubMed Web of Science ®Google Scholar
• Zahroh H, Ma’rup A, Tambunan US, Parikesit AA. Immunoinformatics approach in designing epitope-based vaccine against meningitis-inducing bacteria (Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae type b). Drug Target Insights. 2016;10:19–29. doi:10.4137/DTI.S38458
   PubMed Web of Science ®Google Scholar
• Ren S, Guan L, Dong Y, et al. Design and evaluation of a multi-epitope assembly peptide vaccine against Acinetobacter baumannii infection in mice. Swiss Med Wkly. 2019;149:w20052. doi:10.4414/smw.2019.20052
   PubMed Web of Science ®Google Scholar
• Malonis RJ, Lai JR, Vergnolle O. Peptide-based vaccines: current progress and future challenges. Chem Rev. 2020;120(6):3210–3229. doi:10.1021/acs.chemrev.9b00472
   PubMed Web of Science ®Google Scholar
• Skwarczynski M, Zhao G, Boer JC, et al. Poly(amino acids) as a potent self-adjuvanting delivery system for peptide-based nanovaccines. Sci Adv. 2020;6(5):eaax2285. doi:10.1126/sciadv.aax2285
   PubMed Web of Science ®Google Scholar
• Parvizpour S, Pourseif MM, Razmara J, Rafi MA, Omidi Y. Epitope-based vaccine design: a comprehensive overview of bioinformatics approaches. Drug Discov Today. 2020;25(6):1034–1042. doi:10.1016/j.drudis.2020.03.006
   PubMed Web of Science ®Google Scholar
• Amjadi I, Rabiee M, Hosseini MS, Mozafari M. Synthesis and characterization of doxorubicin-loaded poly(lactide-co-glycolide) nanoparticles as a sustained-release anticancer drug delivery system. Appl Biochem Biotechnol. 2012;168(6):1434–1447. doi:10.1007/s12010-012-9868-4
   PubMedGoogle Scholar
• Park K, Skidmore S, Hadar J, et al. Injectable, long-acting PLGA formulations: analyzing PLGA and understanding microparticle formation. J Control Release. 2019;304:125–134. doi:10.1016/j.jconrel.2019.05.003
   PubMed Web of Science ®Google Scholar
• Duran V, Yasar H, Becker J, et al. Preferential uptake of chitosan-coated PLGA nanoparticles by primary human antigen presenting cells. Nanomedicine. 2019;21:102073. doi:10.1016/j.nano.2019.102073
   PubMed Web of Science ®Google Scholar
• Arafa MG, Girgis GNS, El-Dahan MS. Chitosan-Coated PLGA nanoparticles for enhanced ocular anti-inflammatory efficacy of atorvastatin calcium. Int J Nanomed. 2020;15:1335–1347. doi:10.2147/IJN.S237314
   PubMed Web of Science ®Google Scholar
• Wang Y, Li P, Kong L. Chitosan-modified PLGA nanoparticles with versatile surface for improved drug delivery. AAPS PharmSciTech. 2013;14(2):585–592. doi:10.1208/s12249-013-9943-3
   PubMed Web of Science ®Google Scholar
• Vita R, Overton JA, Greenbaum JA, et al. The immune epitope database (IEDB) 3.0. Nucleic Acids Res. 2015;43(Database issue):D405–D412. doi:10.1093/nar/gku938
   PubMed Web of Science ®Google Scholar
• Vita R, Mahajan S, Overton JA, et al. The Immune Epitope Database (IEDB): 2018 update. Nucleic Acids Res. 2019;47(D1):D339–D343. doi:10.1093/nar/gky1006
   PubMed Web of Science ®Google Scholar
• Fairley SJ, Singh SR, Yilma AN, et al. Chlamydia trachomatis recombinant MOMP encapsulated in PLGA nanoparticles triggers primarily T helper 1 cellular and antibody immune responses in mice: a desirable candidate nanovaccine. Int J Nanomed. 2013;8:2085–2099. doi:10.2147/IJN.S44155
   PubMed Web of Science ®Google Scholar
• Abd Hady WE, Mohamed EA, Soliman OAE, El-Sabbagh HM. In vitro-in vivo evaluation of chitosan-PLGA nanoparticles for potentiated gastric retention and anti-ulcer activity of diosmin. Int J Nanomed. 2019;14:7191–7213. doi:10.2147/IJN.S213836
   PubMedGoogle Scholar
• Skwarczynski M, Toth I. Recent advances in peptide-based subunit nanovaccines. Nanomedicine. 2014;9(17):2657–2669. doi:10.2217/nnm.14.187
   PubMed Web of Science ®Google Scholar
• Azim KF, Hasan M, Hossain MN, et al. Immunoinformatics approaches for designing a novel multi epitope peptide vaccine against human norovirus (Norwalk virus). Infect Genet Evol. 2019;74:103936. doi:10.1016/j.meegid.2019.103936
   PubMed Web of Science ®Google Scholar
• Makadia HK, Siegel SJ. Poly Lactic-co-Glycolic Acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers. 2011;3:1377–1397. doi:10.3390/polym3031377
   PubMed Web of Science ®Google Scholar
• Liang X, Duan J, Li X, et al. Improved vaccine-induced immune responses via a ROS-triggered nanoparticle-based antigen delivery system. Nanoscale. 2018;10(20):9489–9503. doi:10.1039/C8NR00355F
   PubMedGoogle Scholar